Nonuse of statins - A new risk factor for infectious death in cardiovascular patients?

Critical Care Medicine

Volumn 35, Issue 2, 2007, Pages 631-632

  Krüger, Stefan ^a   Merx, Marc W ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Atherosclerosis; Infection; Sepsis; Statins

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ATORVASTATIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; HEART DEATH; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; INFLAMMATION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LOW DRUG DOSE; LUNG INFECTION; MORBIDITY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; STROKE; SURVIVAL;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; SEPSIS;

EID: 33846430527     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000254069.48562.13     Document Type: Editorial

References (14)

1. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
2. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 333:1301-1308
3. Schwartz GG, Olson AG, Ezekowitz MD, et al: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718
4. Almog Y, Novack V, Eisinger M, et al: The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35:372-378
5. Kwak B, Multhaupt F, Myit S, et al: Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-1402
6. Erkkila L, Jauhiainen M, Latinen K, et al: Effect of simvastatin, an established lipidlowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005; 49:3959-3962
7. del Real G, Jimenez-Baranda S, Mira E, et al: Statins inhibit HIV-1 infection by downregulating Rho activity. J Exp Med 2004; 200: 541-547
8. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
9. Merx MW, Liehn EA, Janssens U, et al: HMGCoA reductase inhibitor Simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109:2560-2565
10. Merx MW, Liehn EA, Graf J, et al: Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005; 112:117-124
11. Almog Y, Shefer A, Novack V, et al: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-885
12. Hackam DG, Mamdani M, Li P, et al: Statins in patients with cardiovascular disease: A population-based cohort analysis. Lancet 2006; 367:413-418
13. Merx MW, Weber C: Statins in the intensive care unit. Curr Opin Crit Care 2006; 12:309-314
14. Merx MW, Weber C: Statins: A preventive strike against sepsis in patients with cardiovascular disease? Lancet 2006; 367:372-373